von Groote Thilo, Sadjadi Mahan, Zarbock Alexander
Department of Anaesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany.
Curr Opin Anaesthesiol. 2024 Feb 1;37(1):35-41. doi: 10.1097/ACO.0000000000001320. Epub 2023 Oct 5.
Patients undergoing cardiac surgery are at high risk to develop cardiac surgery-associated acute kidney injury (CS-AKI) postoperatively. CS-AKI is associated with an increased risk for persistent renal dysfunction, morbidity and mortality. This review summarizes the epidemiology and pathophysiology of CS-AKI, as well as current treatment and prevention strategies.
As AKI is a syndrome with complex pathophysiology, no causative treatment strategies exist. Recent advances in the field of AKI biomarkers offer new perspectives on the issue and the implementation of biomarker-guided preventive strategies may reduce rates of CS-AKI. Finally, nephroprotective treatments and angiotensin II as a novel vasopressor may offer new opportunities for high-risk patients undergoing cardiac surgery.
Based on the described novel approaches for early detection, prevention and management of CS-AKI, a precision-medicine approach should be implemented in order to prevent the development of AKI in patients undergoing cardiac surgery.
接受心脏手术的患者术后发生心脏手术相关急性肾损伤(CS-AKI)的风险很高。CS-AKI与持续性肾功能不全、发病率和死亡率增加相关。本综述总结了CS-AKI的流行病学和病理生理学,以及当前的治疗和预防策略。
由于急性肾损伤(AKI)是一种病理生理学复杂的综合征,不存在病因性治疗策略。AKI生物标志物领域的最新进展为该问题提供了新的视角,实施生物标志物指导的预防策略可能会降低CS-AKI的发生率。最后,肾保护治疗和血管紧张素II作为一种新型血管加压药可能为接受心脏手术的高危患者提供新的机会。
基于所描述的CS-AKI早期检测、预防和管理的新方法,应实施精准医学方法以预防接受心脏手术患者发生AKI。